BTG beats full-year expectations as it plans to market Varisolve alone in the US
This article was originally published in Scrip
Executive Summary
BTG's performance in the year ending 31 March beat expectations across the board as its integration of Protherics, which it acquired in December 2008, progressed ahead of schedule.